Genolution Executives Acquire Treasury Shares, Citing "Enhancing Shareholder Value"

Kim Minyi, Co-CEO of Genolution, has acquired additional treasury shares through on-market purchases.

According to Genolution on June 11, CEO Kim acquired 30,451 treasury shares through on-market purchases from June 4 to June 10. In addition, another company executive purchased 4,000 treasury shares on the market. This treasury share acquisition is interpreted as a decision aimed at demonstrating the company’s confidence in its future growth potential, its commitment to enhancing shareholder value, and its resolve for responsible management.

The Genolution management team has continuously purchased treasury shares, demonstrating their trust in the company’s growth potential and corporate value. In particular, despite securing new mid- to long-term growth engines such as increased sales in the molecular diagnostics business, expansion of the RNAi-based green bio business, and accelerated global expansion, they have determined that the current share price does not fully reflect the company’s intrinsic value, leading to the additional acquisition.

A company spokesperson stated, “This treasury share acquisition demonstrates the management’s strong confidence in Genolution’s future growth potential and corporate value,” adding, “It is part of our efforts to align the interests of management and shareholders and to strengthen responsible management.”

This content was produced with the assistance of AI translation services.